Capricor Therapeutics, Inc. (DE:4LN2)
NASDAQ:4LN2
4LN2 Stock Chart & Stats
€25.56
-€0.68(-4.80%)
At close: 4:00 PM EST
€25.56
-€0.68(-4.80%)
Day’s Range― - ―
52-Week Range€3.73 - €30.77
Previous CloseN/A
Volume0.00
Average Volume (3M)73.00
Market Cap
€1.43B
Enterprise Value€1.19B
Total Cash (Recent Filing)€278.61M
Total Debt (Recent Filing)€21.12M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Aug 12, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding57,911,892
10 Day Avg. Volume20
30 Day Avg. Volume73
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.39
Price to Sales (P/S)0.00
P/FCF Ratio-18.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€46.65Price Target Upside82.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.35
Revenue Forecast (FY)€103.28M
Bulls Say, Bears Say
Bulls Say
Pivotal Phase 3 EfficacyStatistically significant Phase 3 efficacy materially lowers clinical risk for approval and supports a meaningful label for Duchenne muscular dystrophy. Durable clinical benefit strengthens prescriber confidence, underpins payer discussions, and improves the long-term commercial potential and lifecycle expansion prospects.
Manufacturing Infrastructure & Scale PlanOwning a validated GMP facility with staged scale-up reduces dependence on third-party CMOs, improves control over quality and supply reliability, and supports margin and launch execution. A clear capacity roadmap aligns manufacturing readiness with potential approval and commercialization timing.
Cash Position & PRV Monetization OpportunityA multi-hundred-million dollar cash buffer provides a durable runway to complete near-term regulatory activities and initial commercial setup without immediate dilution. Potential monetization of a Priority Review Voucher offers optional, non-dilutive capital to extend runway or fund commercialization investments.
Bears Say
Litigation Over U.S. Distribution RightsActive litigation creates material, durable uncertainty for U.S. commercialization: potential injunctions, delayed launches, and the prospect of repaying $50M upfront could disrupt partner arrangements, delay revenue realization, increase legal and execution costs, and distract management during critical launch planning.
No Product Revenue And Rising Operating SpendPersistent zero commercial revenue combined with substantially higher opex accelerates cash burn and raises financing risk beyond current runway. Longer-term sustainability depends on approval, successful commercialization, or additional funding; otherwise the company may face dilution, debt, or constrained execution.
Payer/Pricing And Access ComplexityStructural reimbursement complexity (transfer pricing, ASP/AMP dynamics) can limit uptake even after approval, constraining revenue and patient access. Unresolved payer mechanics materially affect provider willingness to administer an ultra-cold, multi-dose therapy and heighten long-term commercial execution risk.
Capricor Therapeutics News
4LN2 FAQ
What was Capricor Therapeutics, Inc.’s price range in the past 12 months?
Capricor Therapeutics, Inc. lowest stock price was €3.73 and its highest was €30.77 in the past 12 months.
What is Capricor Therapeutics, Inc.’s market cap?
Capricor Therapeutics, Inc.’s market cap is €1.43B.
When is Capricor Therapeutics, Inc.’s upcoming earnings report date?
Capricor Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 47 days.
How were Capricor Therapeutics, Inc.’s earnings last quarter?
Capricor Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -€0.519 earnings per share for the quarter, missing the consensus estimate of -€0.446 by -€0.073.
Is Capricor Therapeutics, Inc. overvalued?
According to Wall Street analysts Capricor Therapeutics, Inc.’s price is currently Undervalued.
Does Capricor Therapeutics, Inc. pay dividends?
Capricor Therapeutics, Inc. does not currently pay dividends.
What is Capricor Therapeutics, Inc.’s EPS estimate?
Capricor Therapeutics, Inc.’s EPS estimate is -0.52.
How many shares outstanding does Capricor Therapeutics, Inc. have?
Capricor Therapeutics, Inc. has 57,911,892 shares outstanding.
What happened to Capricor Therapeutics, Inc.’s price movement after its last earnings report?
Capricor Therapeutics, Inc. reported an EPS of -€0.519 in its last earnings report, missing expectations of -€0.446. Following the earnings report the stock price went down -0.42%.
Which hedge fund is a major shareholder of Capricor Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DE:4LN2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Capricor Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€46.65 (82.52% Upside)
€46.65 (82.52% Upside)
Blogger Sentiment
Bullish
DE:4LN2 Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
202.48%
12-Months-Change
Fundamentals
Return on Equity
-59.27%
Trailing 12-Months
Asset Growth
112.19%
Trailing 12-Months
Company Description
Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
4LN2 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and regulatory progress for deramiocel — statistically significant phase 3 efficacy (primary and cardiac secondary endpoints), robust long-term safety exposure, active BLA review with a clear PDUFA date, in-house manufacturing capabilities and a solid cash runway. Management also articulated a concrete commercialization plan and eligibility for a monetizable Priority Review Voucher. Offsetting these positives are notable near-term risks: an active lawsuit with NS Pharma that creates distribution uncertainty (and potential need to repay $50M), rising operating expenses and no current product revenue, manufacturing labeling constraints for an ultra-cold-chain therapy, and unresolved ASP/AMP payer complexities that could affect access. On balance, the material clinical/regulatory achievements and internal control of manufacturing and cash resources outweigh the legal and commercial execution risks, but the litigation and payer/pricing issues remain important near-term uncertainties.View all DE:4LN2 earnings summaries4LN2 Stock 12 Month Forecast
Average Price Target
€46.65
▲(82.52% Upside)
Technical Analysis
Options Prices
Currently, No data available
---